Picture loading failed.

Anti-PDCD1 therapeutic antibody (Pre-made Budigalimab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1, PCD-1; PDCD1), with potential immune checkpoint inhibitory and antineoplastic activities.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-085-1mg 1mg 3090
GMP-Bios-ab-085-10mg 10mg 21890
GMP-Bios-ab-085-100mg 100mg 148000
GMP-Bios-ab-085-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-PDCD1 therapeutic antibody (Pre-made Budigalimab biosimilar,Whole mAb)
INN Name Budigalimab
TargetPDCD1/PD-1
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-I
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2018
Year Recommended2019
CompaniesAbbVie
Conditions Approvedna
Conditions ActiveColorectal cancer;Ovarian cancer;Small cell lung cancer;Solid tumours;Endometrial cancer;Fallopian tube cancer;HIV-1 infections;Peritoneal cancer;Squamous cell cancer
Conditions Discontinuedna
Development Techna